Pandemic COVID-19 outbreak
Within two decades of surfacing of the severe
acute respiratory syndrome (SARS) in 2002 - 2003, a Middle East respiratory
syndrome coronavirus (MERS-CoV) in 2012, this is the third time that another
fatal virus, coronavirus 2019 (COVID-19) has been detected
in Dec 2019 in Wuhan, China. The world is confronting this emergency.
Internationally, Public Health Emergency has been declared by the World Health
Organization(WHO) on 30th Jan 2020. Pandemic COVID-19 infections
are analysed on the basis of the number of cases in million people per day,
thereby calling for public health emergency.
COVID-19 is an enveloped RNA virus having surface
spikes and has a wide host range. This can fly. Geographic locations, age, and sex
are not the bar of infections. Its mean incubation period is 5.2 days. Key symptoms
are fever, cough associated with pneumonia. Bilateral multiple
lung lobes in the lower and/or periphery position observed by the Chest CT scan. It has to pay attention to the need to develop
effective therapies against the causative agent (Tang
et al., 2020).
The
worldwide recommended molecular test of choice for the diagnosis of COVID-19 is
real-time reverse transcriptase PCR (RT-PCR). Antibody-based techniques are also
being recently used as supplementary tools to detect COVID-19.
Due
to the absence of potential antiviral therapy against COVID-19, current
treatments are primarily focused on symptomatic diagnosis and provision of
respiratory support to the affected patients. Simultaneously, several types of
research have been conducted to develop an effective therapeutic strategy
against COVID-19. According to the scientific research reported till now, some
of the drugs developed by the researchers are illustrated and promising results in the reduction of viral
load among patients have been observed. Most of them are already approved for
other diseases and have acceptable safety profiles. These include protease inhibitors (Lopinavir/Ritonavir),
nucleoside analogs (Remdesivir, Ribavirin, Oseltamivir, Favipiravir), antimalarial drug
(Chloroquine and hydroxychloroquine), anti-inflammatory drug (Camostat Mesylate).
Among these, some drugs are already showing their anti-COVID-19 potential in
clinical trials. Besides drug treatment, other strategies are also employed to
combat COVID-19 disease. For example, to boost the immunity of patients, researchers
use ‘convalescent’ plasma from recovered COVID-19 patients or monoclonal antibodies
directed against COVID-19.
Head, Dept.of Microbiology,
Techno India University,West Bengal
Comments
Post a Comment